Expansion Chemicals & Petrochemicals NSE: TATVA ·

Tatva Chintan Pharma Chem Approves Rs 200 Crore Greenfield Expansion in Gujarat

NSE Filing 4 min read 19 views
Tatva Chintan Pharma Chem Approves Rs 200 Crore Greenfield Expansion in Gujarat

Tatva Chintan Pharma Chem Limited — Expansion · TATVA

Project Value

₹200 Cr

Greenfield Unit

Market Cap

₹3,345.5 Cr

Mid-range Performer

Revenue TTM

₹505.9 Cr

Specialty Chemicals

RSI

68.67

Standard Zone

! Key Highlights

  • Greenfield manufacturing unit to be established at Dahej-III Industrial Estate, Bharuch
  • Installation of 344 kilolitres of aggregate reactor capacity for specialty chemicals
  • Projected investment of approximately Rs 200 Crore funded via internal accruals and debt
  • Implementation timeline estimated at 21 months to meet future market requirements
  • Board approved an increase in borrowing limits from Rs 300 Crore to Rs 1,000 Crore

Tatva Chintan Pharma Chem Limited has announced a significant greenfield expansion at the Dahej-III Industrial Estate in Gujarat with a total investment of Rs 200 Crore. The project aims to install 344 kilolitres of reactor capacity to address the projected growth in global demand for specialty chemicals.

Details of the Dahej Expansion

The company is establishing a new greenfield manufacturing unit at Dahej-III in the Bharuch district of Gujarat. This facility will specifically focus on increasing the manufacturing capacities for various specialty chemicals through the installation of an aggregate reactor capacity of 344 kilolitres. Unlike a simple modification to existing infrastructure, this project represents a completely new manufacturing unit designed to strengthen core infrastructure and address anticipated market requirements.

The total investment of approximately Rs 200 Crore will be financed through a strategic combination of internal accruals and debt instruments, with a target completion window of approximately 21 months from the commencement date.

Strategic Rationale and Financial Flexiblity

  • Strategic location at Dahej Industrial Estate provides logistical advantages for chemical exports and raw material procurement
  • Project targets the anticipated increase in global demand for niche specialty chemicals and structure directing agents
  • Proposed increase in borrowing limits to Rs 1,000 Crore provides a larger financial buffer for capital intensive growth
  • Capacity scale-up of 344 KL enables the company to manage larger international orders and improve supply chain reliability
  • Re-appointment of founding directors ensures management continuity during the execution of this large-scale infrastructure project

Business Overview and Market Performance

Tatva Chintan is a leading integrated specialty chemical company with a diverse product portfolio including phase transfer catalysts and electrolyte salts for supercapacitor batteries. The company maintains a strong market position with a Trendlyne Durability Score of 70 and a promoter holding of 72.02 percent. For the quarter ended June 30, 2026, the company reported a standalone total income of Rs 150.74 Crore, a notable increase from Rs 110.55 Crore in the corresponding quarter of the previous year.

Standalone net profit for the same period reached Rs 10.45 Crore, reflecting improved operational efficiencies and volume growth across its core chemical segments.

Industry Outlook and Demand Drivers

The specialty chemicals industry in India is benefiting from a structural shift toward domestic manufacturing and increased adoption of green chemistry standards. Tatva Chintan's focus on electrolyte salts positions it to capture growth in the energy storage and electric vehicle segments. The proposed capacity expansion aligns with the industry's projected growth trajectory as global manufacturers seek diversified supply sources.

By scaling up its reactor capacity by 344 KL, the company aims to enhance its responsiveness to large-scale international orders and maintain its competitive edge in the niche pharmaceutical and agrochemical intermediates space while catering to future market demands.

Tatva Chintan Pharma Chem Limited — Financial Snapshot

BSE: 543321 · NSE: TATVA · Chemicals & Petrochemicals

Current Market Price ₹1430.2 per share
Market Capitalisation ₹3,345.54 Cr BSE Listed
Revenue (Annual) ₹505.86 Operating
Net Profit (Annual) ₹42.05 Consolidated
P/E Ratio (TTM) 79.55× Sector: 44.8×
Promoter Holding 72.02% 0.00% QoQ
FII Holding 3.93% Current Qtr

Source Verified

Exchange filing by Tatva Chintan Pharma Chem Limited announcing board approval for greenfield capacity expansion and quarterly results. Financial metrics from Trendlyne.

View Filing